Amniotic allografts have moved well beyond chronic wound and burn applications chronic ulcer care For chronic wound applications, see our burns and amniotic membrane evidence summary.. In the perioperative setting, surgeons are increasingly evaluating amniotic-derived materials as adjuncts for incision support, tendon and nerve protection, soft-tissue coverage over exposed anatomy, and modulation of the early inflammatory environment after reconstructive procedures. For foot and ankle, podiatric, and orthopedic teams DFU treatment protocols, the practical question is no longer whether these products are biologically interesting. It is whether they improve healing reliability in cases where wound breakdown, adhesions, delayed closure, or scar-mediated dysfunction can derail an otherwise successful operation.
The evidence base remains heterogeneous, and that point matters. Processing method, graft thickness, form factor, and surgical indication all influence expected performance. Still, published data now support a measured perioperative role for amniotic allografts in selected cases, especially when the operative field includes tenuous soft tissue, exposed tendon or hardware, revision risk, or anatomy where glide planes and scar control are clinically meaningful.
Clinical Evidence
Human surgical data are most developed in foot and ankle and peripheral nerve applications. In total ankle arthroplasty, Gessner et al. evaluated local placement of cryopreserved amniotic membrane-umbilical cord at closure in 104 patients and reported faster skin healing versus controls, with mean time to healing reduced from 40 days to 28.5 days. The study was not powered to show fewer major reoperations, but it supports the concept that biologic augmentation may matter most in soft-tissue vulnerable anterior ankle incisions.
In hallux rigidus surgery, Galli et al. reported a prospective randomized comparison of cheilectomy with or without cryopreserved amniotic membrane-umbilical cord. At 1 year, the biologic group showed better AOFAS and Foot Function Index outcomes, although pain scores improved in both groups and range-of-motion differences were minimal. That is a useful reminder that perioperative allograft value may present as improved recovery quality rather than dramatic early pain separation.
For broader reconstructive lower-extremity surgery, Tacktill et al. described 21 consecutive foot and ankle cases in which dehydrated amnion/chorion was placed over deep tissues during closure. Functional scores improved substantially over follow-up, and the cohort had no wound dehiscence. As a noncomparative series, it should not be read as definitive proof, but it reinforces feasibility in complex lower-extremity reconstruction.
Outside the foot and ankle, the biologic rationale is strongest where scar formation compromises function. In cubital tunnel surgery, Gaspar et al. found that human amniotic membrane wrapping of the ulnar nerve reduced recurrent paresthesia symptoms. In traumatic peripheral nerve repair, Assaf et al. reported favorable nerve regeneration and recovery findings after amniotic wrapping. Spine literature is still limited, but a 2023 systematic review by Walker et al. concluded that available studies suggest potential benefit for reducing epidural adhesions and improving postoperative outcomes, while also emphasizing that preparations and indications are too variable for firm conclusions.
Evidence-Informed Perioperative Protocol
A practical protocol starts with case selection. The strongest rationale exists in revision surgery, anterior ankle approaches, exposed tendon or bone, areas of thin dorsal soft tissue, high-shear closures, and procedures where scar tethering could limit function. Diabetes, smoking history, edema, prior incision compromise, neuropathy, and hardware prominence all raise the threshold for considering biologic reinforcement.
Intraoperatively, most published foot and ankle series place the graft during deep closure rather than on top of the final epithelial surface. The goal is to create a biologically active interface over periosteal, capsular, retinacular, tendon, or neurovascular structures while preserving standard layered closure. The graft should be cut to fit the target zone, laid without bunching, and secured according to the product instructions for use and the surgeon's usual tissue-handling principles. Avoid folding excess material into a confined space that could increase dead space or alter glide.
Postoperatively, management should stay disciplined: edema control, offloading, incision surveillance, and prompt escalation for drainage or skin edge compromise. If a product is selected for irregular geometry or deeper soft-tissue protection, document the operative problem it was intended to address: for example, high-risk anterior ankle closure, exposed extensor mechanism, revision tendon bed, or scar-prone nerve decompression field.
Sheet Matrix vs Micronized/Flowable Format
Format selection should follow anatomy. For surgeons and wound programs evaluating options such as a sheet-based matrix or a micronized amniotic platform, the decision is usually about placement control versus conformability.
| Consideration | Sheet / Dual-Layer Matrix | Micronized or Flowable Platform |
|---|---|---|
| Best use case | Incisions or surgical beds needing discrete coverage over tendon, capsule, periosteum, or exposed anatomy | Irregular topography, tunnels, undermining, or areas where broad conformability is more important than a fixed planar barrier |
| Primary advantage | Controlled placement, easy visualization, barrier-like support | Flexible delivery into complex contours |
| Potential limitation | Less adaptable in narrow recesses or nonplanar defects | Less precise as a mechanical coverage layer over a defined structure |
| Typical perioperative fit | Foot and ankle closure support, tendon coverage, scar-prone operative planes | Complex soft-tissue protection strategies where surface geometry is the main challenge |
For many surgical teams, the real-world decision is not which format is universally better, but which one better matches the surgical problem in front of them. That is where portfolio breadth becomes clinically useful.
Coding and Coverage Considerations
For outpatient wound protocols, see our diabetic foot ulcer treatment guidelines.Coding is where many perioperative biologic discussions lose precision. Coverage rules for chronic DFU and VLU applications should not be automatically extrapolated to operative wound reinforcement, tendon coverage, or nerve wrapping. As of December 24, 2025, CMS stated that the MAC LCDs scheduled for January 1, 2026 for skin substitute grafts/CTPs in DFU and VLU care were withdrawn. Separately, CMS finalized CY 2026 2026 reimbursement coding update payment policy changes for covered skin substitute application procedures, including incident-to supply treatment and a single national payment rate of approximately $127.28 for skin substitute products in those covered pathways.
For perioperative surgical uses outside ulcer-focused application policies, reimbursement remains indication-specific and payer-specific. That means documentation should clearly identify the operative indication, the anatomic target, why standard closure alone was judged insufficient, and how the product was used in the procedure. Wound center coordinators and revenue-cycle teams should verify current payer policy, product coding status, and site-of-care rules before assuming separate payment.
Key Takeaways
- Perioperative amniotic allografts are most defensible in high-risk closures, scar-prone operative planes, and procedures involving exposed tendon, nerve, bone, or hardware.
- Published human data in total ankle arthroplasty, cheilectomy, reconstructive lower-extremity surgery, and nerve wrapping support selective use, but the literature is still mixed and product-specific.
- Format choice should follow anatomy: sheet-based matrices favor controlled barrier coverage, while micronized platforms favor conformability in irregular spaces.
- Documentation must connect the biologic to the operative problem being solved; chronic-wound billing logic does not automatically apply to surgical adjunct use.
References
- Gessner IH, et al. Effects of Cryopreserved Amniotic Membrane-Umbilical Cord Allograft on Total Ankle Arthroplasty Wound Healing. J Foot Ankle Surg. 2019;58(2):236-243.
- Galli SH, Ferguson CM, Davis WH, et al. Cheilectomy With or Without Cryopreserved Amniotic Membrane-Umbilical Cord Allograft for Hallux Rigidus. Foot Ankle Orthop. 2021;6(1):2473011420967999.
- Tacktill JZ, Rasor Z, Adams J, et al. Wound repair, safety, and functional outcomes in reconstructive lower extremity foot and ankle surgery using a dehydrated amnion/chorion allograft membrane. Int Wound J. 2022;19(8):2027-2036.
- Gaspar MP, et al. Human Amniotic Membrane Wrapping of the Ulnar Nerve During Cubital Tunnel Surgery Reduces Recurrence of Symptoms. J Hand Surg Glob Online. 2022;5(2):148-153.
- Assaf M, et al. Effect of Amniotic Membrane Nerve Wrapping in Final Results of Traumatic Peripheral Nerve Repair. World J Plast Surg. 2022;11(2):90-97.
- Walker M, et al. The Effect of Amniotic Tissue on Spinal Interventions: A Systematic Review. Int J Spine Surg. 2023;17(1):32-41.
- Nakagawa H, Sung K, Ashkani-Esfahani S, et al. Plantar fasciitis: a comparison of ultrasound-guided fasciotomy with or without amniotic membrane allograft injection. Regen Med. 2022;17(12):931-940.
- Centers for Medicare & Medicaid Services. Calendar Year 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F). Published November 2025. Accessed April 14, 2026.
- Centers for Medicare & Medicaid Services. Final Local Coverage Determinations (LCDs) for Certain Skin Substitutes Withdrawn. Updated December 24, 2025. Accessed April 14, 2026.
Evaluate Surgical-Fit Biologic Options
Request samples of AmnioAMP or Rampart at nextgenbiologicsusa.com/request-samples
Request Samples